136 related articles for article (PubMed ID: 37162706)
1. Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growth.
Alexanian AR; Stoellinger HM; de Araujo Farias V; Quiñones-Hinojosa A
Invest New Drugs; 2023 Jun; 41(3):371-375. PubMed ID: 37162706
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibiting moderate effect on normal stem cells growth.
Alexanian A; Stoellinger H; De Araujo Farias V; Quinones-Hinojosa A
Res Sq; 2023 Mar; ():. PubMed ID: 36993520
[TBL] [Abstract][Full Text] [Related]
3. Unique combinations of epigenetic modifiers synergistically impair the viability of the U87 glioblastoma cell line while exhibiting minor or moderate effects on normal stem cell growth.
Alexanian AR; Brannon A
Med Oncol; 2022 Apr; 39(5):86. PubMed ID: 35478054
[TBL] [Abstract][Full Text] [Related]
4. Specific combinations of the chromatin-modifying enzyme modulators significantly attenuate glioblastoma cell proliferation and viability while exerting minimal effect on normal adult stem cells growth.
Alexanian AR; Huang YW
Tumour Biol; 2015 Nov; 36(11):9067-72. PubMed ID: 26084611
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic pathways and glioblastoma treatment: insights from signaling cascades.
Allen BK; Stathias V; Maloof ME; Vidovic D; Winterbottom EF; Capobianco AJ; Clarke J; Schurer S; Robbins DJ; Ayad NG
J Cell Biochem; 2015 Mar; 116(3):351-63. PubMed ID: 25290986
[TBL] [Abstract][Full Text] [Related]
7. An update on the epigenetics of glioblastomas.
Ferreira WA; Pinheiro Ddo R; Costa Junior CA; Rodrigues-Antunes S; Araújo MD; Leão Barros MB; Teixeira AC; Faro TA; Burbano RR; Oliveira EH; Harada ML; Borges Bdo N
Epigenomics; 2016 Sep; 8(9):1289-305. PubMed ID: 27585647
[TBL] [Abstract][Full Text] [Related]
8. Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth.
Lee J; Shin YJ; Lee K; Cho HJ; Sa JK; Lee SY; Kim SH; Lee J; Yoon Y; Nam DH
Cancer Res Treat; 2018 Jul; 50(3):1009-1022. PubMed ID: 29129044
[TBL] [Abstract][Full Text] [Related]
9. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
Li Q; Dong C; Cui J; Wang Y; Hong X
J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Epigenetic Modifier Drug Combination for Synergistic Effect against Glioblastoma Multiform Cancer Cell Lines.
Soleiman M; Fathi-Roudsari M; Khajeh K; Maghsoudi A
Cancer Invest; 2024 Apr; 42(4):319-332. PubMed ID: 38695671
[TBL] [Abstract][Full Text] [Related]
11. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
12. Graphene oxide suppresses the growth and malignancy of glioblastoma stem cell-like spheroids via epigenetic mechanisms.
Wang X; Zhou W; Li X; Ren J; Ji G; Du J; Tian W; Liu Q; Hao A
J Transl Med; 2020 May; 18(1):200. PubMed ID: 32410622
[TBL] [Abstract][Full Text] [Related]
13. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells.
Sherry MM; Reeves A; Wu JK; Cochran BH
Stem Cells; 2009 Oct; 27(10):2383-92. PubMed ID: 19658181
[TBL] [Abstract][Full Text] [Related]
14. Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line.
Barciszewska AM; Belter A; Gawrońska I; Giel-Pietraszuk M; Naskręt-Barciszewska MZ
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108161
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression.
Tseng JH; Chen CY; Chen PC; Hsiao SH; Fan CC; Liang YC; Chen CP
Oncotarget; 2017 Feb; 8(9):14666-14679. PubMed ID: 28108734
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modulation of metabolism in glioblastoma.
Dong Z; Cui H
Semin Cancer Biol; 2019 Aug; 57():45-51. PubMed ID: 30205139
[TBL] [Abstract][Full Text] [Related]
17. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glioblastoma proliferation, invasion, and migration by Urolithin B through inducing G0/G1 arrest and targeting MMP-2/-9 expression and activity.
Eidizade F; Soukhtanloo M; Zhiani R; Mehrzad J; Mirzavi F
Biofactors; 2023 Mar; 49(2):379-389. PubMed ID: 36310375
[TBL] [Abstract][Full Text] [Related]
19. Functional importance of glucose transporters and chromatin epigenetic factors in Glioblastoma Multiforme (GBM): possible therapeutics.
Chamarthy S; Mekala JR
Metab Brain Dis; 2023 Jun; 38(5):1441-1469. PubMed ID: 37093461
[TBL] [Abstract][Full Text] [Related]
20. High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors.
Cunha PP; Costa PM; Morais CM; Lopes IR; Cardoso AM; Cardoso AL; Mano M; Jurado AS; Pedroso de Lima MC
Hum Mol Genet; 2017 Nov; 26(22):4375-4387. PubMed ID: 28973155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
